Ships from British Columbia, Canada|No Customs, No Border Delays|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|Ships from British Columbia, Canada|No Customs, No Border Delays|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|Ships from British Columbia, Canada|No Customs, No Border Delays|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|Ships from British Columbia, Canada|No Customs, No Border Delays|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|
All Comparisons

CJC-1295 vs Tesamorelin

Research material comparison: purity standards, available formats, molecular data, batch COA documentation, and regulatory status. For in vitro research use only.

CJC-1295: DTesamorelin: A
AttributeCJC-1295Tesamorelin
CategoryGrowth Hormone SecretagogueGrowth Hormone Secretagogue
Evidence RatingD — PreclinicalA — FDA Approved
Clinical StatusResearch-only / Not approved for human useFDA-approved (Egrifta SV 2019, Egrifta WR March 2025) for HIV-associated lipodystrophy
MechanismCJC-1295 binds to GHRH receptors (GHRHR) on pituitary somatotroph cells, activating intracellular cAMP signaling to stimulate both the transcription of the GH gene and pulsatile release of endogenous growth hormone, which in turn increases IGF-1 levels. The released IGF-1 travels to muscle tissue fo...Tesamorelin binds to and stimulates human GRF (growth hormone-releasing factor) receptors on the anterior pituitary with similar potency as endogenous GRF, stimulating synthesis and release of endogenous growth hormone. This increases IGF-1 and IGFBP-3 levels, leading to increased lipolysis and redu...
Half-LifeNo DAC (mod GRF 1-29): ~30 min; With DAC: ~8 days~26–38 minutes
Bioavailability——
Molecular WeightNo DAC: ~3367.9 g/mol; With DAC: ~3647.3 g/mol~5135.9 g/mol
WADA StatusProhibitedProhibited
Research Half-LifeNo DAC (mod GRF 1-29): ~30 min; With DAC: ~8 days~26–38 minutes
Key Use Cases
  • Anti-Aging
  • Body Composition
  • Body Composition
Safety Concerns
  • Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief
  • Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient)
  • Water retention and edema (dose-dependent; elevated GH causes sodium/water retention via kidneys)
  • Common: injection site reactions (17%), arthralgia (13%), myalgia (6%), peripheral edema (6%)
  • Headache, nausea, and flu-like symptoms reported
  • May increase blood glucose -- monitoring recommended in diabetics
Contraindications
  • Active malignancy or history of cancer (GH promotes cell proliferation)
  • Pregnancy and breastfeeding
  • Pituitary tumors or prior pituitary surgery
  • Diabetes or pre-diabetes (risk of insulin resistance from sustained GH elevation)
  • Pregnancy (Category X -- absolute contraindication)
  • Active cancer or history of any tumor (benign or malignant)
  • Pituitary gland disorder, tumor, or history of pituitary surgery
  • History of head injury or radiation treatment to the head
Regulatory (US)Not FDA-approved. Research chemical only. WADA-banned under Section S2 (growth factors and related substances).FDA-approved: Egrifta SV (Oct 2019) and Egrifta WR (March 2025) for HIV-associated lipodystrophy. Prescription only.

Research Material Specifications

Catalog specifications for the corresponding research materials, including batch documentation coverage.

SpecificationCJC-1295Tesamorelin
Purity Standard≥98%≥98%
CAS NumberN/A218949-48-5
Molecular FormulaBlendC₂₂₃H₃₇₀N₇₂O₆₉S
Available Formats10mg, 5mg, 10mg10mg
Batch COAs Published3 on file1 on file
Stock StatusIn stockIn stock

Availability at Volta Peptides

CJC-1295 No DAC + Ipamorelin 10mg (5+5)

≥98% purity · HPLC verified · In stock

$49

Tesamorelin 10mg

≥98% purity · HPLC verified · In stock

$64

Research Disclaimer: This comparison is provided for educational purposes only. All products are sold exclusively for in vitro research use. The information presented is based on published preclinical and clinical research and does not constitute medical advice. Consult a qualified healthcare professional before making any decisions regarding peptide use.

Explore More
Comparisons

Compare any two peptides side-by-side or browse our curated popular matchups.

All ComparisonsBrowse Catalog

Your Cart

Your cart is empty

Browse our catalog to add research compounds.